Sulphamoprine
Suppliers
Names
[ CAS No. ]:
155-91-9
[ Name ]:
Sulphamoprine
[Synonym ]:
Sulfanilsaeure-(4,6-dimethoxy-pyrimidin-2-ylamid)
Sulphamoprine
Sulfadimethoxypyrimidine
2-p-Aminobenzenesulfonamido-4,6-dimethoxypyrimidine
sulphadimethoxine
sulfadimethoxine
4-Amino-N-(4,6-dimethoxy-2-pyrimidinyl)benzenesulfonamide
Benzenesulfonamide, 4-amino-N-(4,6-dimethoxy-2-pyrimidinyl)-
SDmP
sulfanilic acid-(4,6-dimethoxy-pyrimidin-2-ylamide)
6-(p-aminobenzenesulphonamido)-2,4-dimethoxypyrimidine
4-Amino-N-(4,6-dimethoxypyrimidin-2-yl)benzenesulfonamide
Sulfamoprine
ICI 3435
Sulphadimethoxypyrimidine
4-amino-N-(4,6-dimethoxy-pyrimidin-2-yl)-benzenesulfonamide
Chemical & Physical Properties
[ Density]:
1.4±0.1 g/cm3
[ Boiling Point ]:
570.7±60.0 °C at 760 mmHg
[ Melting Point ]:
200ºC
[ Molecular Formula ]:
C12H14N4O4S
[ Molecular Weight ]:
310.329
[ Flash Point ]:
298.9±32.9 °C
[ Exact Mass ]:
310.073578
[ PSA ]:
124.81000
[ LogP ]:
1.41
[ Vapour Pressure ]:
0.0±1.6 mmHg at 25°C
[ Index of Refraction ]:
1.623
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- DA9495000
- CHEMICAL NAME :
- Benzenesulfonamide, 4-amino-N-(4,6-dimethoxy-2-pyrimidinyl)-
- CAS REGISTRY NUMBER :
- 155-91-9
- BEILSTEIN REFERENCE NO. :
- 0307123
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 7
- MOLECULAR FORMULA :
- C12-H14-N4-O4-S
- MOLECULAR WEIGHT :
- 310.36
- WISWESSER LINE NOTATION :
- T6N CNJ BMSWR DZ& DO1 FO1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 28 gm/kg/28D-I
- TOXIC EFFECTS :
- Liver - hepatitis (hepatocellular necrosis), zonal Blood - normocytic anemia Related to Chronic Data - death
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 2,149,1947 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 538 mg/kg
- SEX/DURATION :
- female 1-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Effects on Newborn - physical
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1 gm/kg
- SEX/DURATION :
- female 14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - stillbirth
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 825 mg/kg
- SEX/DURATION :
- female 1-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 500 mg/kg
- SEX/DURATION :
- female 11-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - skin and skin appendages
- REFERENCE :
- EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 21,151,1965
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 2520 mg/kg
- SEX/DURATION :
- female 1-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 2520 mg/kg
- SEX/DURATION :
- female 1-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
Safety Information
[ Hazard Codes ]:
Xi
[ Risk Phrases ]:
36/37/38-43
[ Safety Phrases ]:
26-36/37-24/25-23
[ HS Code ]:
2935009090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2935009090
[ Summary ]:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%